Brokerages forecast that Akorn, Inc. (NASDAQ:AKRX) will post $252.74 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Akorn’s earnings, with estimates ranging from $243.20 million to $260.83 million. Akorn posted sales of $280.73 million during the same quarter last year, which suggests a negative year over year growth rate of 10%. The company is expected to report its next earnings report on Monday, January 1st.

On average, analysts expect that Akorn will report full-year sales of $252.74 million for the current financial year, with estimates ranging from $1.03 billion to $1.06 billion. For the next fiscal year, analysts expect that the firm will report sales of $1.09 billion per share, with estimates ranging from $1.03 billion to $1.15 billion. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Akorn.

Several equities research analysts have recently commented on the stock. TheStreet raised shares of Akorn from a “c+” rating to a “b-” rating in a research report on Thursday, April 20th. Royal Bank Of Canada set a $34.00 target price on shares of Akorn and gave the stock a “hold” rating in a research report on Saturday, May 27th. William Blair downgraded shares of Akorn from an “outperform” rating to a “market perform” rating in a research report on Tuesday, April 25th. Jefferies Group LLC downgraded shares of Akorn from a “buy” rating to a “hold” rating and boosted their target price for the stock from $24.00 to $34.00 in a research report on Tuesday, April 25th. Finally, Craig Hallum downgraded shares of Akorn from a “buy” rating to a “hold” rating in a research report on Tuesday, April 25th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $30.55.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its position in Akorn by 12,960.9% in the first quarter. BlackRock Inc. now owns 9,080,983 shares of the company’s stock worth $218,671,000 after buying an additional 9,011,455 shares during the last quarter. Vanguard Group Inc. boosted its position in Akorn by 4.0% in the first quarter. Vanguard Group Inc. now owns 6,945,369 shares of the company’s stock worth $167,245,000 after buying an additional 267,203 shares during the last quarter. William Blair Investment Management LLC boosted its position in Akorn by 8.0% in the first quarter. William Blair Investment Management LLC now owns 4,492,169 shares of the company’s stock worth $108,171,000 after buying an additional 333,086 shares during the last quarter. FMR LLC boosted its position in Akorn by 54.0% in the first quarter. FMR LLC now owns 3,560,997 shares of the company’s stock worth $85,748,000 after buying an additional 1,249,329 shares during the last quarter. Finally, Columbia Wanger Asset Management LLC boosted its position in Akorn by 127.5% in the first quarter. Columbia Wanger Asset Management LLC now owns 2,682,821 shares of the company’s stock worth $64,602,000 after buying an additional 1,503,366 shares during the last quarter. Hedge funds and other institutional investors own 76.09% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.americanbankingnews.com/2017/07/23/252-74-million-in-sales-expected-for-akorn-inc-nasdaqakrx-this-quarter.html.

Shares of Akorn (NASDAQ:AKRX) traded down 0.15% during midday trading on Friday, reaching $33.60. 3,516,788 shares of the company traded hands. The company has a 50-day moving average of $33.48 and a 200 day moving average of $27.81. The firm has a market capitalization of $4.19 billion, a PE ratio of 22.94 and a beta of 1.36. Akorn has a 12-month low of $17.61 and a 12-month high of $35.40.

About Akorn

Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.

Get a free copy of the Zacks research report on Akorn (AKRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related companies with MarketBeat.com's FREE daily email newsletter.